Overview
Actively managed equity portfolio investing worldwide in biotech companies.
Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
UBS's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of UBS SA国际传谋.
Risks
Features
| Product category |
UBS Equity Funds UBS Sector Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 (Americas) LLC, New York
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS Europe SE, sucursal en España
|
| Day of inception |
October 15, 1996
|
| Currency of account |
USD
|
| Close of financial year |
November 30
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
2.11% p.a.
|
| Management fee |
1.63% p.a.
|
| Total expense ratio (TER) |
2.09% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI US Investable Market Biotechnology 10/40 Index (r)
|
| ISIN |
LU0069152568
|
| Bloomberg Ticker |
UBSEBIO LX
|
| Telekurs Id |
EQBIO
|
Performance and Prices
Percentage growth
as of April 23, 2026| USD(%) | EUR(%) | |
| YTD | ||
| 1M | ||
| 3M | ||
| 6M | ||
| 1Y | ||
| 2Y | 36.26 | 20.14 |
| 3Y | ||
| 5Y | 18.86 | 22.29 |
| ø p.a.5Y | 3.52 | 4.11 |
Current data
| Net asset value | 23.04.2026 | USD 918.89 |
| High - last 12 months | 24.02.2026 | USD 947.46 |
| Low - last 12 months | 14.05.2025 | USD 591.38 |
| Assets of the unit class in mn | 23.04.2026 | USD 404.39 |
| Total product assets in mn | 23.04.2026 | USD 463.30 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 16.63% | 17.01% |
| Sharpe Ratio | 31.03.2026 | 0.45 | 0.00 |
| Risk Free Rate | 31.03.2026 | 4.55% | 3.51% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| Vertex Pharmaceuticals Inc | 9.08 |
| Insmed Inc | 6.35 |
| Ionis Pharmaceuticals Inc | 4.44 |
| Gilead Sciences Inc | 3.97 |
| Roivant Sciences Ltd | 3.84 |
| AbbVie Inc | 3.80 |
| Arrowhead Pharmaceuticals Inc | 3.68 |
| Amgen Inc | 3.65 |
| Royalty Pharma PLC | 3.34 |
| Denali Therapeutics Inc | 3.22 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
| Prospectus |
|
| Key Information Document |
|
| Past performance |
|
| Previous performance scenario |
|
| Statutes / Management regulations |
|
| ESG Disclosure |
|
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
| Annual report |
|
| SFDR Periodic Report Annex |
|
| Semi-annual report |
|